3-(5-甲基-1,3,4-恶二唑-2-基)苯胺 | 122733-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(5-甲基-1,3,4-恶二唑-2-基)苯胺
• 英文名称: 3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenylamine
• 英文别名: 3-(5-methyl-1,3,4-oxadiazol-2-yl) benzenamine；3-(5-methyl-[1,3,4]oxadiazol-2-yl)phenylamine；3-(5-Methyl-1,3,4-oxadiazol-2-yl)aniline
• CAS: 122733-40-8
• 化学式: C₉H₉N₃O
• mdl: MFCD11052289
• 分子量: 175.19
• InChiKey: AZLVMRYJNAZIBG-UHFFFAOYSA-N

物化性质

• 沸点：
  374.8±44.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-(5-甲基-1,3,4-恶二唑-2-基)苯胺 、 1-[5-bromo-2-(2,4-difluorobenzyloxy)phenyl]-pentane-1,4-dione 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 2-(3-{2-[5-bromo-2-(2,4-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}phenyl)-5-methyl-[1,3,4]oxadiazole
  参考文献：
  名称：

  Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists

  摘要：

  Replacement of the carboxylic acid group in a series of previously described 1,5-biaryl pyrrole EP1 receptor antagonists led to the discovery of various novel non-acidic antagonists. Several analogues displayed high binding affinity and high binding efficiency indices. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.021
• 作为产物：
  描述：

  间硝基苯甲酸 生成 3-(5-甲基-1,3,4-恶二唑-2-基)苯胺
  参考文献：
  名称：

  [EN] 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS
  [FR] SELS DE 1,3,4-BENZOTRIAZEPINE ET LEUR UTILISATION COMME LIGANDS DU RECEPTEUR DE CCK

  摘要：

  该发明涉及公式（I）化合物的药用可接受盐，其中：W为N或N+-O-；R2为可选择取代的C1至C18烃基团，其中最多三个C原子可选择地被N、O和/或S原子取代。R3为-(CR11R12)m-X-(CR13R14)p-R9；m为0、1、2、3或4；p为0、1或2；X为键、-CR15=CR16-、-C≡C-、C(O)NH、NHC(O)、C(O)NMe、NMeC(O)、C(O)O、NHC(O)NH、NHC(O)O、OC(O)NH、NH、O、CO、SO2、SO2NH、C(O)NHNH；R9为H、C1至C6烷基或苯基、萘基、吡啶基、苯并咪唑基、吲哚基、喹啉基、异喹啉基、四氢异喹啉基、吲哚啉基、异吲哚啉基、吲哚基、异吲哚基或2-吡啶酰基，取代为-L-Q。R4为可选择取代的C1至C18烃基团，其中最多三个C原子可选择地被N、O和/或S原子取代；这些盐可用于治疗胃泌素相关疾病。

  公开号：

  WO2004101533A1

文献信息

• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET MÉTHODES UTILISÉS POUR LA MODULATION DES KINASES ET INDICATIONS À CET EFFET
  申请人：PLEXXIKON INC

  公开号：WO2011063159A1

  公开（公告）日：2011-05-26

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些方法来治疗疾病和病况，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病况，包括黑色素瘤、胶质瘤、胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病况，包括急性疼痛、慢性疼痛或多囊肾病。
• [EN] DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDRO-CYCLOPENTA-ISOQUINOLINE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2021130255A1

  公开（公告）日：2021-07-01

  The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

  本发明涉及式（I）的二氢环戊基异喹啉衍生物，其制备方法，含有它们的药物组合物以及它们在治疗由IgE引起的疾病（如过敏反应、非过敏肥大细胞反应或某些自身免疫反应）中的用途，特别是由IgE与FcεRI受体相互作用引起的疾病。
• P 2 X 4 RECEPTOR ANTAGONIST
  申请人：Ushioda Masatoshi

  公开号：US20130178625A1

  公开（公告）日：2013-07-11

  A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X 4 receptor antagonist: wherein each of R 11 and R 12 is hydrogen, C 1-8 alkyl or the like; R 13 is hydrogen, C 1-8 alkyl or the like; R 14 is hydrogen, C 1-8 alkyl, C 1-8 alkoxy, C 1-8 alkyl having 1-3 halogens, C 1-8 hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C 1-8 alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and the condensed ring consisting of W 1 and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.

  具有以下式子（II）或其药理学上可接受的盐的化合物可用作P2X4受体拮抗剂： 其中，R11和R12中的每一个都是氢，C1-8烷基或类似物； R13是氢，C1-8烷基或类似物； R14是氢，C1-8烷基，C1-8烷氧基，具有1-3个卤素的C1-8烷基，C1-8羟基烷基，卤素，羟基，硝基，氰基，氨基，C1-8烷基氨基，苯磺酰氨基（可选取代基），杂环基（可选取代基）或类似物；并且由W1和相邻苯环组成的缩环是萘、四氢萘或茚环。
• Substituted amide inhibitors of cholesterol absorption
  申请人：Warner-Lambert Company

  公开号：US04824843A1

  公开（公告）日：1989-04-25

  Novel N-(substituted-phenyl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamides which are useful in preventing the intestinal absorption of cholesterol, as well as novel pharmaceutical compositions and methods of use, as well as processes for their manufacture are herein described.

  本文描述了新型N-(取代苯基)-5-(2,5-二甲基苯氧基)-2,2-二甲基戊酰胺类化合物，它们对预防胆固醇在肠道吸收方面具有有用的作用，同时还描述了新型的制药组合物和使用方法以及它们的制造过程。
• [EN] BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS<br/>[FR] BENZOTRIAZEPINES UTILISEES COMME LIGANDS DE RECEPTEURS DE CHOLECYSTOQUININE ET DE GASTRINE
  申请人：BLACK JAMES FOUNDATION

  公开号：WO2003041714A1

  公开（公告）日：2003-05-22

  This invention relates to a compound of formula (I) wherein: W is N or N+-O-; and R1 to R5 are as defined in the description, for use for the treatment of gastrin related disorders.

  本发明涉及式(I)的化合物，其中：W为N或N+-O-; R1至R5如描述中所定义，用于治疗胃泌素相关疾病。